Approval Of Medtronic’s Renal Denervation System Delayed By COVID-19
Executive Summary
Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.
You may also be interested in...
Medtronic Pushes Completion Of Pivotal Renal Denervation Trial To Late 2022
The company announced that results from the pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system will not be available until the trial completes enrollment next year. The company previously expected to be able to present favorable interim results from the trial in November.
Cardiovascular Catch-Up: Spring Brings Bloom Of New Clinical Trial Results And Launches
April and May were full of cardiovascular professional society conferences, yielding important new research results along with announcements of major new clinical trials. Here are a few of the highlights.
SoniVie, ReCor Move Forward With Ultrasound Renal Denervation Technologies
The FDA granted its breakthrough designation to SoniVie’s TIVUS and ReCor's Paradise ultrasound renal denervation systems for treating hypertension.